Flag of the European Union EU Clinical Trials Register Help

Clinical trials for NVA237 OR umeclidinium OR 573719 OR glycopyrrolate OR glycopyrronium OR tiotropium OR aclidinium

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    287 result(s) found for: NVA237 OR umeclidinium OR 573719 OR glycopyrrolate OR glycopyrronium OR tiotropium OR aclidinium. Displaying page 6 of 15.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2007-003648-31 Sponsor Protocol Number: M/273FO/22 Start Date*: 2007-09-04
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: A phase IIa, randomised, multicentre, evaluator-blinded, 4-way crossover clinical trial to study the pharmacokinetics, safety, tolerability and effects on lung function of one day treatment of form...
    Medical condition: Twenty-four moderate to severe COPD patients will be included in the study.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000116-14 Sponsor Protocol Number: M-40464-39 Start Date*: 2013-08-08
    Sponsor Name:ALMIRALL, S. A., Research and Development (R&D) Centre
    Full Title: A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF TWICE-DAILY ACLIDINIUM BROMIDE /FORMOTEROL FUMARATE COMPARED WITH TWICE-DAILY S...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) IT (Completed) LT (Completed) CZ (Completed) AT (Completed) ES (Completed) NL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-000460-90 Sponsor Protocol Number: AGO/2006/002 Start Date*: 2006-03-09
    Sponsor Name:University Hospital Ghent
    Full Title: Echocardiographic study of the haemodynamic effects of remifentanil with and without glycopyrrolate in healthy children
    Medical condition: ASA I and II children
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011600-27 Sponsor Protocol Number: M/34273/34 Start Date*: 2009-08-10
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD)
    Medical condition: Moderate to severe chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Prematurely Ended) FR (Completed) ES (Completed) DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016251-21 Sponsor Protocol Number: 205.458 Start Date*: 2010-10-29
    Sponsor Name:Boehringer Ingelheim
    Full Title: Pharmacokinetics and dose-ranging of tiotropium inhalation solution delivered from the Respimat inhaler in patients with Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-013763-19 Sponsor Protocol Number: CQAB149BIT01 Start Date*: 2009-09-24
    Sponsor Name:NOVARTIS FARMA
    Full Title: Multicenter, randomized, blinded, placebo controlled, cross over, single dose study to assess the effect of indacaterol (150 �g) versus tiotropium (18 �g) on Inspiratory Capacity in moderate COPD p...
    Medical condition: moderate COPD
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029978 Obstructive chronic bronchitis with acute exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003373-10 Sponsor Protocol Number: M/34273/47 Start Date*: 2014-03-18
    Sponsor Name:ALMIRALL S.A.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, 2 PERIOD CROSSOVER CLINICAL STUDY TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE 400 ΜCG BID ON COPD SYMPTOMS AND SLEEP QUALITY AFTER 3 WEEKS OF TREATMENT IN PATIENT...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004710-42 Sponsor Protocol Number: 1237.20 Start Date*: 2012-04-23
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) DK (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-000188-33 Sponsor Protocol Number: MK-8616-146 Start Date*: 2017-10-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or ...
    Medical condition: Reversal of neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10018061 General anesthesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001495-69 Sponsor Protocol Number: 2008/0801 Start Date*: 2008-07-11
    Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille
    Full Title: Réversibilité sous Tiotropium (SPIRIVA®) chez les patients BPCO : paramètres EFR, dyspnée et TDM
    Medical condition: Traitement bronchodilatateur continu destiné à soulager les symptômes des patients présentant une bronchopneumopathie chronique obstructive (BPCO).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000883-16 Sponsor Protocol Number: 200699 Start Date*: 2014-07-03
    Sponsor Name:GlaxoSmithKline Research & Devlopment Ltd
    Full Title: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination with Fluticasone Furoate in COPD Subjects with an Asthmatic Component
    Medical condition: COPD Subjects with an Asthmatic Component
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    17.1 100000004855 10009028 Chronic obstructive asthma (with obstructive pulmonary disease) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003413-33 Sponsor Protocol Number: TBB-COPD-201 Start Date*: 2012-12-10
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Randomized, Open-Label, Repeat Dosing (7 days), Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered via Breath Actuated Inhaler (BAI)...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007944-33 Sponsor Protocol Number: CQAB149B2348 Start Date*: 2009-03-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase IIIb multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150 μg o.d. vs inhaled tiotropium 18 μg o.d...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) FI (Completed) SK (Completed) CZ (Completed) LT (Completed) IS (Completed) BE (Completed) PT (Completed) EE (Completed) DK (Completed) LV (Completed) HU (Completed) DE (Completed) FR (Completed) NL (Completed) PL (Completed) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005913-35 Sponsor Protocol Number: DB2116132 Start Date*: 2012-06-27
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002665-38 Sponsor Protocol Number: M/34273/40 Start Date*: 2011-10-05
    Sponsor Name:Almirall S.A.
    Full Title: A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, 2 PERIOD CROSSOVER CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE 400 μg BID ON EXERCISE ENDURANCE IN PATIENTS WITH STABLE ...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005318-50 Sponsor Protocol Number: M-40464-33 Start Date*: 2015-05-04
    Sponsor Name:AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden
    Full Title: A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE FIXED-DOSE COMBINATION ON LUNG HYPERINFLATION, ...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005087-26 Sponsor Protocol Number: 1237.4 Start Date*: 2008-06-25
    Sponsor Name:Boehringer Ingelheim GmbH & Co. KG
    Full Title: Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination with 5µg ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002264-24 Sponsor Protocol Number: 1237.26 Start Date*: 2013-11-14
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium+ oldaterol fixed...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) SK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019047-19 Sponsor Protocol Number: 03-2010 Start Date*: 2010-05-10
    Sponsor Name:Pneumologia c/o Villa Pineta
    Full Title: ADDITIONAL EFFECT OF TIOTROPIUM BROMIDE ON EXERCISE TOLERANCE IN COPD PATIENTS. PILOT STUDY
    Medical condition: COPD (Chronic Obstructive Pulmonary Disease)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-010668-40 Sponsor Protocol Number: 1237.5 Start Date*: 2011-07-29
    Sponsor Name:Boehringer Ingelheim bv [...]
    1. Boehringer Ingelheim bv
    2. Boehringer Ingelheim bv
    Full Title: A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μ...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) PT (Completed) SI (Completed) CZ (Completed) DE (Completed) HU (Completed) DK (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 06 19:57:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA